- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: TAS-115 | TAS115
Compound class: Synthetic organic
Comment: Pamufetinib (TAS-115) is a dual MET/VEGFR2(KDR) receptor tyrosine kinase inhibitor . It was designed by Taiho Pharmaceutical as a potential anticancer drug . It is a Type 1 ATP competitive inhibitor.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T, Suzuki T et al.. (2013)
The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
Mol Cancer Ther, 12 (12): 2685-96. [PMID:24140932]
2. Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L. (2016)
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Eur J Med Chem, 108: 495-504. [PMID:26717201]